Specific Antiviral Drugs For COVID 19 Market Report 2026

Specific Antiviral Drugs For COVID 19 Market Overview

• Specific Antiviral Drugs For COVID 19 market size has reached to $15.23 billion in 2025 • Expected to grow to $33.17 billion in 2030 at a compound annual growth rate (CAGR) of 16.8% • Growth Driver: Rise In COVID-19 Cases The Growth Of The Market Due To Increasing Demand For Antiviral Treatments • Market Trend: Oral Antiviral Innovations Enhance COVID-19 Treatment Accessibility And Effectiveness • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Specific Antiviral Drugs For COVID 19 Market?

Specific antiviral drugs for COVID-19 are medications designed to directly target and inhibit the replication or function of the SARS-CoV-2 virus, which causes COVID-19. These drugs help reduce the severity and duration of the infection by interfering with viral processes such as entry, replication, or assembly. The main types of specific antiviral drugs for COVID-19 come in tablet and injection forms. Tablets are solid pharmaceutical dosage forms that contain a precise amount of active medicinal ingredient(s) along with excipients, compressed into a small, usually flat or oval shape. These antiviral drugs are indicated for use in hospitalized patients, non-hospitalized patients, and for preventive treatment. The drug classes include nucleoside analogues, protease inhibitors, RNA polymerase inhibitors, entry inhibitors, and monoclonal antibodies, and they are administered via various routes such as oral, intravenous, subcutaneous, and inhalation. These medications are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and other outlets.

What Is The Specific Antiviral Drugs For COVID 19 Market Growth Forecast?

The specific antiviral drugs for covid 19 market size is expected to see rapid growth in the next few years. It will grow to $33.17 billion in 2030 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to development of next-generation antiviral drugs, increased public-private partnerships, rising preventive treatment adoption, expansion of combination therapies, integration of personalized medicine approaches. Major trends in the forecast period include rising investment in covid-19 antiviral drug development, increasing adoption of oral antiviral tablets, growth in monoclonal antibody therapies, expansion of hospital and retail distribution channels, focus on targeted treatment for hospitalized and high-risk patients.

Global Specific Antiviral Drugs For COVID 19 Market Segmentation

1) By Type: Tablet, Injection 2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment 3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies 4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments: 1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets 2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

What Is The Driver Of The Specific Antiviral Drugs For COVID 19 Market?

The rising number of COVID-19 cases is expected to propel the growth of the specific antiviral drugs for the COVID-19 market going forward. COVID-19 cases refer to individuals who tested positive for the SARS-CoV-2 virus, which causes COVID-19. The rising number of COVID-19 cases is due to the emergence of new variants that spread more easily and can partially evade immunity from vaccines or past infections. Specific antiviral drugs for COVID-19 help reduce the severity and duration of the illness, improving patient outcomes and lowering the overall burden of COVID-19 cases. For instance, in May 2025, according to the World Health Organization, a Switzerland-based global public health agency, reported that the Eastern Mediterranean region's test positivity rate jumped from 4% to 17% in early 2025, surpassing the same period in 2024. Therefore, the rising number of COVID-19 cases drives the growth of the specific antiviral drugs for the COVID-19 market.

Key Players In The Global Specific Antiviral Drugs For COVID 19 Market

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

Global Specific Antiviral Drugs For COVID 19 Market Trends and Insights

Major companies operating in the specific antiviral drugs for the COVID-19 market are focusing on developing innovative therapies, such as oral antiviral therapies, to enhance treatment accessibility and effectiveness. Oral antiviral therapies are medications taken by mouth to inhibit the replication of viruses like COVID-19, offering a convenient and effective treatment option. For instance, in March 2024, Shionogi And Co., a Japan-based pharmaceutical company, launched Xocova and obtained full standard approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the antiviral drug ensitrelvir. Additionally, it also offers post-exposure prophylaxis by significantly reducing the risk of developing symptomatic COVID-19 in exposed individuals and shortens symptom duration with a favorable safety profile.

What Are Latest Mergers And Acquisitions In The Specific Antiviral Drugs For COVID 19 Market?

In July 2024, GSK plc, a UK-based pharmaceutical company, collaborated with CureVac to develop and commercialize next-generation mRNA vaccines for COVID-19 and influenza. This collaboration aims to develop and commercialize innovative mRNA vaccines for influenza and COVID-19 to improve global public health outcomes. CureVac N.V. is a Germany-based company that develops therapies based on messenger RNA (mRNA) technology.

Regional Insights

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Specific Antiviral Drugs For COVID 19 Market?

The specific antiviral drugs for COVID-19 market consists of sales of host-directed antivirals, immunomodulators, fusion inhibitors, helicase inhibitors, and tmprss2 inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Specific Antiviral Drugs For COVID 19 Market Report 2026?

The specific antiviral drugs for covid 19 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the specific antiviral drugs for covid 19 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.